Back

CytoSorb data show 37% reduction in severe bleeding during urgent CABG

Verifying
  • CytoSorbents reported matched real-world evidence linking CytoSorb with less severe bleeding during urgent CABG.
  • 37% relative reduction was recorded, with severe bleeding rates of 21.8% versus 34.5% for controls.
  • CytoSorbents plans a new FDA De Novo submission for DrugSorb-ATR in early 2027.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.